Doxycycline in Acute Traumatic Brain Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-01

Study Completion Date

2020-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

evaluate the impact of Doxycycline on both clinical outcome and blood levels of NSE in patients with TBI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis

NCT01205464

Fatigue Radicular Pain Cognitive Dysfunction +2 more

COMPLETED NA

Side Effects and Adherence Associated With Doxycycline Use Following Medical Abortion

NCT01799252

Abortion

COMPLETED

Safety and Effect of Doxycycline in Patients With Amyloidosis

NCT01677286

Amyloidosis

COMPLETED PHASE2

Doxycycline for Hereditary Hemorrhagic Telangiectasia

NCT03397004

Hereditary Hemorrhagic Telangiectasia (HHT)

COMPLETED PHASE2

Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis

NCT02553473

Neuroborreliosis, Borrelia Burgdorferi

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damnhour University.
2. All Participants agreed to take part in this clinical research and provide informed consent. for unconscious participants, the informed consent was obtained from their legally authorized representative.
3. Patients with moderate to severe TBI will be enrolled from Tanta university hospitals.
4. Serum samples will be collected for measuring the biomarkers.
5. Our design is randomized, controlled study.
6. All enrolled patients will be divided into 2 groups, Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days, and group (2) will be 25 patients will receive placebo in addition to the standard treatment.
7. All patients will be followed up during ICU period.
8. Statsicial tests appropriate to the study design will be conducted to evaluate the significance of the results.
9. Measuring outcome: the primary outcome is the change in the serum level of acute brain injury biomarkers.
10. Results, conclusions, discussion and recommendations will be given.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Doxycycline

Group (1) 25 patients that receive doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days.

Group Type ACTIVE_COMPARATOR

Doxycycline 100 MG Oral Tablet

Intervention Type DRUG

doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day

Placebo

group (2) will be 25 patients will receive placebo in addition to the standard treatment.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

placebo in addition to the standard treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doxycycline 100 MG Oral Tablet

doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day

Intervention Type DRUG

placebo

placebo in addition to the standard treatment.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

vibramycine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Hospital admission in the first 24 h of injury,
2. 18 to 90 years of age and
3. Both sexes with moderate to severe traumatic brain injury (GCS score ≤ 12).
4. Able to tolerate enteral feeding and drug administration within the first 24 hours of TBI

Exclusion Criteria

1. Hypersensitivity to tetracyclines
2. Pregnant and breast feeding women,
3. History of autoimmune disease.
4. History of receiving chronic steroid treatment and isotretinoin,
5. Pre-existing hepatic (AST, ALT greater than 3 times the upper limit of normal) or renal failure (BUN/ Creatinine 20:1; creatinine \> 2 mg/dL),
6. Known malignancies

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No